Prostate Cancer | Specialty

The prostate cancer condition center is a comprehensive resource for clinical news and expert insights on prostate cancer. Read more at OncLive.

Real-World Treatment Gaps in mCRPC Reinforce the Need for Personalized Selection and Sequencing

July 23rd 2025

Jue Wang, MD, discusses persisting gaps between clinical advances and real-world care and the evolving role of personalized treatment strategies in mCRPC.

Key Takeaways in mCSPC: Combination Therapy and Germline Testing Is the New Standard of Care

July 23rd 2025

Panelists discuss how androgen deprivation therapy (ADT) monotherapy is no longer acceptable for metastatic castration-sensitive prostate cancer (mCSPC), emphasizing that combination therapy with androgen receptor (AR) pathway inhibitors or chemotherapy plus universal germline testing should be the new standard of care.

Expert Perspectives: ARANOTE: Subgroup Analysis in Black Patients

July 23rd 2025

Panelists discuss how the ARANOTE trial’s subgroup analysis of 65 Black patients (primarily from Brazil and South Africa) demonstrated consistent treatment benefits and highlights the importance of diversity in clinical trials to address health care disparities and potential biological differences across populations.

Talazoparib Plus Tazemetostat Is Safe, Generates Signs of Clinical Benefit in mCRPC

July 22nd 2025

The combination of talazoparib and tazemetostat was safe and led to PSA reductions in certain patients with metastatic castration-resistant prostate cancer.

Dr McKay on the Safety of Olaparib and Radium-223 in mCRPC With Bone Metastases

July 22nd 2025

Rana R. McKay, MD, FASCO, discusses the safety profiles of olaparib plus radium-223 vs radium-223 monotherapy in mCRPC.

Darolutamide Plus ADT Gains EU Approval for mHSPC

July 21st 2025

Darolutamide receives EU approval with ADT for metastatic hormone-sensitive prostate cancer.

HARMONY Study Aims to Personalize PARP Inhibition in mHSPC Through Adaptive Design, Diverse Patient Enrollment

July 21st 2025

Qian (Janie) Qin, MD, discusses the importance of early molecular testing, evolving PARP inhibitor strategies, and the phase 2 HARMONY trial in mHSPC.

Interpreting ARANOTE: Darolutamide in Doublet and Triplet Therapy for Metastatic Castration-Sensitive Prostate Cancer

July 16th 2025

Panelists discuss how the ARANOTE trial’s progression-free survival benefits with darolutamide inform treatment selection between doublet and triplet approaches, emphasizing personalized decision-making based on tumor burden, patient performance status, and the “first shot, best shot” treatment philosophy.

Long-Term Efficacy of Doublets—the ARCHES 5-Year Update

July 16th 2025

Panelists discuss how the ARANOTE trial’s quality-of-life data and the ARCHES trial’s 5-year follow-up demonstrate sustained benefits of doublet therapy, with enzalutamide plus ADT showing a 3-year overall survival improvement in high-volume patients.

Lutetium Lu 177 Vipivotide Tetraxetan Positioned for Earlier Use in mCRPC While Radium-223 Sequencing Requires Further Clarification

July 15th 2025

Qian (Janie) Qin, MD, discusses the current arsenal of radioligand therapies in metastatic castration-resistant prostate cancer.

Early Safety Data Show Tolerability of Apalutamide Plus Carotuximab in Metastatic CRPC

July 15th 2025

Apalutamide plus carotuximab has been demonstrated to be well tolerated in patients with metastatic castration-resistant prostate cancer

Pasritamig Displays Safety, Durable Disease Control in Heavily Pretreated mCRPC

July 14th 2025

Pasritamig was safe and produced durable responses in heavily pretreated metastatic castration-resistant prostate cancer.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Dr Saad on the Efficacy and Safety of Radium-223 Plus Enzalutamide in mCRPC

July 11th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy and safety data from the PEACE study of radium-223 and enzalutamide in mCRPC.

Enzalutamide Plus Leuprolide Yields OS Benefit in nmHSPC With Biochemical Recurrence

July 10th 2025

The combination of enzalutamide and leuprolide improved OS vs leuprolide alone in nmHSPC with high-risk biochemical recurrence at high risk for metastasis.

Dr Morgans on the Influence of HRQOL Data on the Use of Darolutamide Plus ADT in mHSPC

July 9th 2025

Alicia Morgans, MD, MPH, discusses how PRO data from the ARANOTE trial could inform the selection of darolutamide plus ADT for patients with mHSPC.

FDA Grants Fast Track Designation to TRE-515 Plus Radioligand Therapy in PSMA+ mCRPC

July 9th 2025

TRE-515 has received FDA fast track designation in combination with radioligand therapy for PSMA-positive mCRPC.

Emerging Trials and the Future of Biomarker-Driven Therapy in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field toward increasingly complex, biomarker-driven treatment selection.

Choosing a Chemotherapy-Based Triplet Regimen in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how the ARASENSE and PEACE-1 phase 3 trials demonstrated the efficacy of triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and novel antiandrogens, while addressing the ongoing underutilization of intensified treatment approaches.

EU Approval Is Sought for Niraparib/Abiraterone Acetate Dual-Action Tablet in mHSPC With HRR Gene Alterations

July 7th 2025

European approval is being sought for the combination of niraparib, abiraterone acetate, and prednisone or prednisolone for HRR-mutated mHSPC.